Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Cholangiocarcinoma.

Journal Article (Review;Journal Article)

Cholangiocarcinoma (CCA), a malignant tumor that occurs in the epithelium of the biliary tract, has a very poor prognosis because affected patients are frequently diagnosed at an advanced stage and recurrence after resection is common. Over the last two decades, our understanding of the molecular biology of this malignancy has expanded, and various studies have explored targeted therapy for CCA in order to improve patient survival. The histone acetylation/deacetylation equilibrium is affected in carcinogenesis, leading to altered chromatin structure and therefore changes in gene expression. Understanding the molecular identity of histone deacetylases (HDACs), their cellular interactions and potential role as anticancer agents will help us develop new therapeutic strategies for CCA-affected patients. Furthermore, HDAC inhibitors act on cellular stress response pathways and decrease cancer angiogenesis. Downregulation of pro-angiogenic genes such as vascular endothelial growth factor (VEGF), hypoxia inducible factor-1 (HIF-1), and endothelial nitric oxide synthase (eNOS) inhibit formation of new vessels and can negatively affect the metastatic process. Finally, recent clinical trials prove that administration of both HDAC inhibitors and DNA-targeting chemotherapeutic agents, such as topoisomerase inhibitors, DNA intercalating agents, inhibitors of DNA synthesis, covalently modifying DNA agents, and ionizing radiation, maximizes the anticancer effect by increasing the cytotoxic efficiency of a variety of DNA-damaging anticancer drugs. Therefore, combination therapy of classic chemotherapeutic drugs with HDAC inhibitors can act synergistically for the patients' benefit.

Full Text

Duke Authors

Cited Authors

  • Mastoraki, A; Schizas, D; Charalampakis, N; Naar, L; Ioannidi, M; Tsilimigras, D; Sotiropoulou, M; Moris, D; Vassiliu, P; Felekouras, E

Published Date

  • April 2020

Published In

Volume / Issue

  • 24 / 2

Start / End Page

  • 175 - 184

PubMed ID

  • 32125662

Electronic International Standard Serial Number (EISSN)

  • 1179-2000

International Standard Serial Number (ISSN)

  • 1177-1062

Digital Object Identifier (DOI)

  • 10.1007/s40291-020-00454-x


  • eng